Rapid Micro Biosystems (NASDAQ:RPID) Raised to Hold at Wall Street Zen

Rapid Micro Biosystems (NASDAQ:RPID) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.00.

Rapid Micro Biosystems Price Performance

RPID opened at $2.30 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.36 and a current ratio of 3.31. The stock has a market capitalization of $104.56 million, a PE ratio of -2.15 and a beta of 1.38. The stock’s 50 day moving average price is $3.90 and its 200-day moving average price is $3.56. Rapid Micro Biosystems has a 52-week low of $1.86 and a 52-week high of $4.94.

Rapid Micro Biosystems (NASDAQ:RPID) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05). The business had revenue of $11.28 million during the quarter, compared to analysts’ expectations of $10.93 million. Rapid Micro Biosystems had a negative return on equity of 95.40% and a negative net margin of 140.30%. On average, equities research analysts predict that Rapid Micro Biosystems will post -1.1 EPS for the current year.

Insider Transactions at Rapid Micro Biosystems

In related news, COO John J. Addington Wilson sold 9,603 shares of Rapid Micro Biosystems stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $4.32, for a total transaction of $41,484.96. Following the completion of the transaction, the chief operating officer directly owned 316,762 shares of the company’s stock, valued at $1,368,411.84. This trade represents a 2.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Sean M. Wirtjes sold 17,254 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $3.92, for a total transaction of $67,635.68. Following the transaction, the chief financial officer directly owned 563,674 shares of the company’s stock, valued at $2,209,602.08. This represents a 2.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 249,705 shares of company stock worth $1,021,364 in the last ninety days. 29.96% of the stock is owned by company insiders.

Hedge Funds Weigh In On Rapid Micro Biosystems

Several institutional investors and hedge funds have recently modified their holdings of RPID. Hudson Bay Capital Management LP purchased a new stake in Rapid Micro Biosystems during the 3rd quarter valued at about $38,000. Fifth Lane Capital LP purchased a new position in Rapid Micro Biosystems in the fourth quarter worth about $51,000. American Century Companies Inc. lifted its stake in shares of Rapid Micro Biosystems by 46.1% in the second quarter. American Century Companies Inc. now owns 16,922 shares of the company’s stock worth $58,000 after buying an additional 5,341 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in shares of Rapid Micro Biosystems during the fourth quarter valued at approximately $71,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Rapid Micro Biosystems during the fourth quarter valued at approximately $72,000. 52.60% of the stock is currently owned by institutional investors.

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.